DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares ...
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-Ma...
DBV Technologies Announces Resignation of Board Member Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board. “Since joi...
DBV Technologies annonce la démission d’un membre de son Conseil d’administration Châtillon, France, le 18 septembre 2025 DBV Technologies annonce la démission d’un membre de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la “Société” ou “DBV”), une société biopharmaceutique au stade clinique, a annoncé ce jour la démission de Daniel Soland de ses fonctions d’administrateur au sein du Conseil d’administration de la Société (le « Conseil »), avec effet immédiat. “Au nom du Conseil, de l’équipe de direction de DBV et de nos act...
While the DAX year-to-date has clearly outperformed most of the large European and US indexes (except the IBEX), many corporates presenting at the 16th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, were still focused on the macroeconomic environment, geopolitical tensions and tariffs and the related impact on their sectors. Unsurprisingly, the clearly most positive sector was defence. For others, the picture was more mixed inside the sectors. Based on the feedb...
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an at-the-market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited ...
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société biopharmaceutique au stade clinique, a annoncé ce jour l’enregistrement d’un supplément au prospectus (« prospectus supplement ») auprès de la U.S. Securities and Exchange Commission (la « SEC ») aux Etats-Unis dans le cadre de la mise en place d’un programme de fina...
ODDO BHF and Commerzbank are jointly hosting the 16th edition of the Corporate Conference on 3 and 4 of September 2025 in Frankfurt am Main. This year, we are welcoming 85 German small, mid and large cap companies. Here are the first messages compiled by our analysts from day 2. We would highlight, notably, a positive tone from Bilfinger, Deutz, GEA, Indus, Jungheinrich, KION Group, Nordex, Stabilus, Thyssenkrupp, TUI and Vonovia Neutral tone from Continental, Dermapharm, DHL Group, E.ON, Frapor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.